Regina Leung, MBA
Jim Sergi, MSN
Richard Moran, PhD
Stephen Mendel, JD
Stacy Evans, MD, MBA
Daniel Jorgensen MD, MPH, MBA
Jeff Lietzke, JD, MA
Shahab Fatheazam MA, MBA
Vice Chairman of Lincoln’s Global Healthcare Group and Board Member, Baylor College of Medicine
Donald Glazer, JD
Board of director, BeiGene and
Board of Trustees, GMO Trust
Amb. George Hara, MSc, MBA
Special Advisor to the Cabinet Office of the Prime Minister of Japan
Professor, Graduate School of Medicine, Osaka University, Japan
Honorary Professor of Medicine, Medicine Faculty, Chinese University of Hong Kong
James Hawkins, PhD, MBA
Managing Director, Focus Investment Banking
Eric Mattson, MBA
Principal, Excellere Partners
Dennis Steadman, MSc
Co-Founder/Chairman, Exubrion Therapeutics and ex-President, Merck
Dinar Dhond, MBA
Richard A. Moran, PhD, MBA
Rich is a San Francisco based business leader, workplace pundit, bestselling author, and venture capitalist. He is best known for his series of humorous business books beginning with bestselling, Never Confuse a Memo with Reality and is credited with starting the genre of “Business Bullet Books.” Rich is the founding partner of Blue Book Ventures. Rich previously served as CEO and vice chairman at Accretive Solutions, a national professional services firm with a focus on accounting, information technology and outsourcing. Accretive Solutions was sold in December 2017 to Resources Global Professionals. Prior to Accretive Solutions, Rich served as a partner at Venrock Ventures and Chairman of the board at Portal Software, which was sold to Oracle for $220M. Rich serves as an Investment advisor to numerous emerging biopharma companies including: SiSaf, Siembra Mobile, CavoGene, and AxoProtego, as well as a variety of start-ups in media and entertainment. Rich also served as President of Menlo College, a private four year college located in Silicon Valley.
The Moran Family owns and operates a vineyard and winery in Knights Valley in Sonoma County. Moran chronicles the development of the vineyard and restoring an old house in his column “In the Country” which has been running in wine country newspapers since 1997
Stephen Mendel, JD
Stephen has served in a wide variety of leadership roles in public and private technology based organizations – founder and managing director and executive vice president of In-Q-Tel in charge of its venture capital activities, vice chairman of Knowledge Revolution (acquired by MSC Software), CEO and president of Ithaca Software (acquired by Autodesk), executive vice president of Maxwell Communication Corporation (MCC), executive vice president of Spectrum-Holobyte (acquired by Hasbro) and executive vice president of MDL (acquired by MCC and then acquired by Symyx Technologies). He has also served as a member of the board of directors of AXS, Ithaca Software, Spectrum-Holobyte, MDL, Simmedia, Verso, Futurize Now, Knowledge Revolution, Direct Language, Site Technologies, Tenor (acquired by Google), LoungeBuddy (acquired by American Express), 2lemetry (acquired by Amazon and renamed AWS IoT), Motive Medical Intelligence and DuckDuckGo. Stephen’s management style and business acumen have been recognized both regionally and nationally. Under his leadership, Ithaca Software was recognized by Inc. Magazine as one of the fastest growing private companies in America. Stephen’s hands-on approach to mentoring young management teams has generated an enviable track record of successful investments. He has spoken at numerous national and international conferences on topics ranging from entrepreneurship to exit strategies.
Stephen began his career as an attorney at Feldman Waldman and Kline, where he represented clients in mergers & acquisitions, corporate, securities, intellectual property and commercial matters. He received his Juris Doctor with highest honors from Hofstra University and his Bachelor of Arts in Philosophy from the University of Rochester.
Dan Jorgensen, MD, MPh, MBA
Dan is an accomplished physician executive with over 22 years of Industry experience in executive leadership in emerging and large biopharma companies including C-level positions for the past 9 years. Dan’s background includes clinical research and development, and commercialization experience for small molecules, biologics/vaccines, and devices, across multiple therapeutic areas, particularly infectious diseases, immunology/inflammation, and diabetes. Previously, Dan served as the Global Clinical Leader at Pfizer for azithromycin and was named Pfizer’s first Vaccine Development Team Leader, playing a key role in multiple regulatory submissions. Prior to joining Industry, Dan was an Epidemic Intelligence Service (EIS) Officer at the Centers for Disease Control & Prevention (CDC) and served as Montana’s State Medical Officer. Dr. Jorgensen was educated at Yale (BS); Univ. of Wisconsin (MD); Univ. of Washington (MPH); and Yale (MBA) and holds board certifications in Pediatrics, Infectious Diseases, and Preventive Medicine.
Jeffrey Lietzke, JD, MA
Jeff’s work supports and catalyzes strategic business development goals, revenue growth, and compliance. Jeff has served in blended legal and executive leadership roles with STERIS Corporation, Integra LifeSciences Corporation, and currently, CAO of the Theken Group. After launching in the 1990s, each of these three ventures wrote exemplary tech-startup stories: STERIS and Integra have become publicly-traded $1+ billion multinationals, and Theken’s first exit closed for $200 million. STERIS, Integra, and Theken blend healthcare innovation with resolute leadership, generating sustained successes.
In 1999, Jeff first worked with serial entrepreneur Randy Theken’s medical technology ventures as outside corporate counsel. Jeff spurred growth by negotiating the ventures’ first national commercialization deal. He joined the current “Theken Group” full-time at its 2013 founding. Jeff serves as General Counsel, and as CAO on the senior executive team. He leads both corporate development and legal initiatives. Theken Group remains a set of privately-held orthopedic innovation ventures building on Theken’s traditions and successful 2009 exit transaction. Jeff’s corporate development interests include co-founding Theken’s young “LaunchPoint” division, with its strategic focus on scaling commercial innovation in medical technologies, healthcareIT, and advanced medical materials.
A Cornell Law graduate with economics degrees from the University of Akron (MA) and The College of Wooster (B.A.), Jeff has served as an Adjunct Professor at Case Western School of Law, and Weatherhead School of Management.
Stacy Evans, MD, MBA
Stacy is a much sought over Executive Consultant for the biopharma industry with over 20 years of business development, strategy, commercial development, and outcomes research experience. Stacy serves as the Chief Business Officer of Avillion, LLP, a Blackstone-backed clinical development and financing company structuring and negotiating investments > $100M. Stacy has also supported a variety of small and emerging biotech companies with corporate fund raising, strategic partnerships, commercial development, and pipeline prioritization. Previously, Stacy spent 12 years at Pfizer where he held roles in New Product Development, Commercial Strategy, and Business/Corporate Development. As a Senior Transaction Lead at Pfizer and as an Executive Consultant for various biopharma companies, he has been responsible for successfully leading up to multi-billion M&A and licensing deals. Stacy earned a BS in Biochemistry and MD at McGill University, and an Executive MBA at Columbia University.
Regina Leung, MBA
Prior to co-founding tonic bioventures, Regina was the Founder of MayFlower Health, a consulting firm that supports commercialization strategies including brand, managed markets and market entry for pharmaceutical and medical devices companies. Prior to MayFlower Health, Regina has worked in commercial roles within large biopharmaceutical companies such as Bristol-Myers Squibb, PDL Pharma and Gilead Sciences as well at McKesson, a global life sciences distributor where she started the first generic drugs portfolio program for the hospital market and holds a patent for an oncology practice management solution. Regina also worked as a market access Principal at IQVIA and CapGemini, headed their West Coast business and supporting market access strategies for large brands including Enbrel, Aimovig and Actemra and medical devices such as Dexcom. Regina serves as an advisor to various accelerators including SkyDeck (University California at Berkeley) and California Life Sciences Institute (CLSI) and is an exit advisor at Keiretsu Capital. Regina holds an undergraduate degree in Biological Chemistry from the University of Warwick, England and an MBA from University of Southern California.
Jim Sergi, MSN
Prior to co-founding tonic bioventures, Jim was the Founder and the President of CSSi LifeSciences, a global drug discovery and technology development company providing fully integrated, specialized regulatory and clinical services for pharmaceutical and medical device companies. CSSi LifeSciences has created over 5 NewCos with their existing academic partners and has invested and contributed to raise over $700MM in capital. Prior to this role, Jim was the founder and managing partner of Bay Tower Capital, a life sciences merchant bank (i.e., Sigma, Guardsman) and the founder and CEO of ProED Communications, a healthcare services and drug development company, which was acquired by OmniCom. Jim has been responsible for over 85 successful NDA/BLA approvals and over 250 medical device approvals. His academic and medical experience includes Director of Experimental Therapeutics at the Cleveland Clinic Cancer Center, Associate Professor of Medical-Surgical Nursing at the Case Western Reserve University and Lecturer for Oncology at Cleveland State University. He has authored over 50 peer reviewed publications and has numerous issued patents. Jim serves a scientific reviewer for the NIH SBIR/STTR Commercial Readiness Program, as well as a mentor to the NIH/NHLBI and the NIH Larta FeedForward programs. He also serves as a scientific advisor and board member to numerous nonprofits, private equity and venture backed investment firms, including, Defta Partners, and Riverside Capital Partners. Jim has an undergraduate degree in nursing from Edinboro University of Pennsylvania and graduate degrees from the University of Akron.
Kristin Johnson has over a decade of transactional and operational experience. She began her career as an investment banking analyst in technology mergers & acquisitions, and went on to manage investments at In-Q-Tel, the venture capital fund of the CIA. While at In-Q-Tel she held board positions on Spotfire (sold to Tibco) and Rosum (sold to TruePosition) and managed investments in Wispry (acquired by AAC Technologies), Cassatt, and Dust Mesh Networks (acquired by Linear Technologies). Kristin led venture investing and M&A at Nestle, before moving to an operational role in which she managed product development, FP&A, sales and marketing for an $850 million Nestle business unit. Kristin has held board positions on three non-profit organizations and focuses her time volunteering and fundraising for CureSMA, a non-profit organization supporting patients with Spinal Muscular Atrophy.